Details

Autor(en) / Beteiligte

• LeNoue-Newton, Michele L
• Chen, Sheau-Chiann
• Stricker, Thomas
• Hyman, David M
• Blauvelt, Natalie
• Bedard, Philippe L
• Meric-Bernstam, Funda
• Punglia, Rinaa S
• Schrag, Deborah
• Lepisto, Eva M
• Andre, Fabrice
• Smyth, Lillian
• Dogan, Semih
• Yu, Celeste
• Wathoo, Chetna
• Levy, Mia
• Eli, Lisa D
• Xu, Feng
• Mann, Grace
• Lalani, Alshad S
• Ye, Fei
• Micheel, Christine M
• Arnedos, Monica

Titel

Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE

Ist Teil von

• Clinical cancer research, 2022-05, Vol.28 (10), p.2118-2130

Ort / Verlag

United States

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• We wanted to determine the prognosis and the phenotypic characteristics of hormone receptor-positive advanced breast cancer tumors harboring an ERBB2 mutation in the absence of a HER2 amplification. We retrospectively collected information from the American Association of Cancer Research-Genomics Evidence Neoplasia Information Exchange registry database from patients with hormone receptor-positive, HER2-negative, ERBB2-mutated advanced breast cancer. Phenotypic and co-mutational features, as well as response to treatment and outcome were compared with matched control cases ERBB2 wild type. A total of 45 ERBB2-mutant cases were identified for 90 matched controls. The presence of an ERBB2 mutation was not associated with worse outcome determined by overall survival (OS) from first metastatic relapse. No significant differences were observed in phenotypic characteristics apart from higher lobular infiltrating subtype in the ERBB2-mutated group. ERBB2 mutation did not seem to have an impact in response to treatment or time-to-progression (TTP) to endocrine therapy compared with ERBB2 wild type. In the co-mutational analyses, CDH1 mutation was more frequent in the ERBB2-mutated group (FDR < 1). Although not significant, fewer co-occurring ESR1 mutations and more KRAS mutations were identified in the ERBB2-mutated group. ERBB2-activating mutation was not associated with a worse OS from time of first metastatic relapse, or differences in TTP on treatment as compared with a series of matched controls. Although not significant, differences in coexisting mutations (CDH1, ESR1, and KRAS) were noted between the ERBB2-mutated and the control group.